Abstract:Abstract Background To primarily evaluate the effects and safety of a selective angiotensin II type 1 (AT1) receptor blocker (ARB) allisartan isoproxil combined with amlodipine or indapamide in the treatment of patients with essential hypertension who failed allisartan monotherapy. Methods Patients aged 18–75 years with mild-to-moderate essential hypertension [office systolic blood pressure (SBP) 140 to <180 and/or office diastolic blood pressure (DBP) 90 to <110 mm Hg] in 44 study centers between 2016 and 2018 were recruited. Allisartan isoproxil tablet 240 mg was administered per day for 4 weeks, and continued for 8 weeks if office blood pressure (BP) achieved the target of SBP/DBP <140/90 mm Hg. The nonachievers were 1:1 randomly divided into allisartan isoproxil 240 mg + indapamide sustained-release tablet 1.5 mg, or allisartan isoproxil 240 mg + amlodipine besylate 5 mg groups for further 8 weeks of combined therapy. The BP target achieving rate, reduction of sitting BP from baseline, safety and compliance were evaluated as the primary efficacy endpoint. Results A total of 2,212 patients were enrolled, among them 2,126 patients were included in the efficacy analysis, with an average age of 55.1 ± 10.2 years. A total of 1,463 cases (68.8%) were effective after 4 weeks allisartan treatment, and the mean SBP and DBP were significantly decreased by 14.7 ± 12.2 and 8.0 ± 8.4 mm Hg compared with the baseline levels (all P < 0.001). In nonachievers, allisartan combined with indapamide for 8 weeks significantly lowered the sitting BP (SBP/DBP) by 14.0 ± 12.2/8.3 ± 9.2 mm Hg, respectively, compared with 4 weeks monotherapy with allisartan with a BP targeting rate of 57.7% (169/293). In the allisartan + amlodipine group, the SBP/DBP were significantly decreased by (14.4 ± 12.1/8.2 ± 8.2) mm Hg, respectively, with a BP targeting rate of 62.8% (181/288). There was no statistical significance in BP reduction, targeting rate, or adverse reactions between the 2 combined therapies. Conclusions Allisartan isoproxil combined with indapamide or amlodipine can further improve the BP targeting rate when allisartan monotherapy failed in essential hypertension. The 2 combined therapies have similar efficacy and safety.

Antihypertensive Effects of Irbesartan Single and Combined Treatments on 60 Patients with Mild to Moderate Essential Hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

The Combination of Perindopril and Indapamide in Treatment of Essential Hypertension

Comparison of efficacy and tolerability of felodipine ER monotherapy and combined felodipine ER and losartan in patients with essential hypertension

Effects of monolithic compound preparations based on angiotensin II receptor antagonist on the prognosis of patients with hypertension

Comparison of Two Single-Pill Combinations in the Treatment of Elderly Hypertensive Patients

The Effects Between Single Long-Acting and Combination of Short-Acting Antihypertensive Drugs Treatment on Visit-to-visit Systolic Blood Pressure Variability

Effects of losartan,indapamide alone or combined treatment on blood pressure, serum potassium and uric acid levels

Effects and Safety of Allisartan Isoproxil Combined with Amlodipine or Indapamide in Patients with Hypertension Who Failed Allisartan Monotherapy

The Effect of Measuring Times on the Blood Pressure Values with Electronic Automatic Blood Pressure Monitor

Synergism of Irbesartan and Amlodipine on Hemodynamic Amelioration and Organ Protection in Spontaneously Hypertensive Rats

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Efficacy of telmisartan/hydrochlorothiazide in patients with mild to moderate primary hypertension using ambulatory blood pressure monitoring

Irbesartan Hydrochlorothiazide Clinical Efficacy of Treatment of Essential Hypertension

Short-term therapeutic effect and safety of combined benazepril and lercanidipine for mild-moderate hypertension

Effect of Felodipine combined irbesartan on the quality of sexual activity in hypertensive women

Evaluation of the efficacy and safety of domestic irbesartan in treatment of primary hypertension

Effect of Benidipine-atorvastatin Combination Therapy on Inflammatory Markers and Flow-mediated Dilatation in Elderly Patients with Isolated Systolic Hypertension

A Double-Blind, Placebo-Controlled Trial On The Antihypertensive Treatment Effect Of A Quadruple Single-Pill Combination

Effect of Combined Antihypertensive Therapy on the Erectile Function in Male Hypertensives

The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial.